Manuel Battegay - Selected Publications#

Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, and Zinkernagel RM. Enhanced establish-ment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol, 68:4700-4704, 1994

Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM., Grakoui A, Rice CM, Kuro-kohchi K, Berzofsky JA, Hoofnagle JH, Feinstone SM, and Akatsuka T. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus encoded peptides binding to HLA-A2.1 molecules. J Virol, 69:2462-2470, 1995

Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, and Bat-tegay M, for the Swiss HIV Cohort Study. Impact of new antiretroviral combination therapies in HIV infected pa-tients in Switzerland: prospective multicentre study. Brit Med J, 315:1194-1199, 1997

Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Ber-nasconi E, Rickenbach M, Egger M, and Battegay M, for the Swiss HIV Cohort Study. CD4 T-lymphocyte recov-ery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years. The Swiss HIV Cohort Study. Arch Intern Med, 163:2187-2195, 2003

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Ricken-bach M, Hirschel B, Battegay M, and the Swiss HIV Cohort. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/µL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Inf Dis, 41:361-371, 2005

Gasser O, Bihl FK, Wolbers M, Loggi E, Steffen I, Hirsch HH, Günthard HF, Walker BD, Brander C, Battegay M, Hess C, for the Swiss HIV Cohort Study. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Medicine, 4 (3: e96):0556-0561, 2007

Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet, 372:293-299, 2008

Khanna N, Wolbers M, Mueller N, Garzoni C, Cavassini M, Fux C, Vernazza P, Bernasconi E, Viscidi R, Koralnik IJ, Battegay M, Hirsch HH, for the Swiss HIV Cohort Study. JCV-Specific Immune Responses in HIV-1 Patients with Progressive Multifocal Leukoencephalopathy. J Virol, 83(9):4404-4411, 2009

Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, Vernazza P, Bernasconi E, Battegay M, Hirsch HH, for the Swiss HIV Cohort Study. Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study. Clin Inf Dis, 48:1459-1466, 2009

Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A, Vernazza P, Khoo S, Ledergerber B, Back D, Battegay M, the Swiss HIV Cohort Study. Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15:413-423, 2010

Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Bat-tegay M, and the Swiss HIV Cohort Study.Treatment modification in HIV-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Int Med, 170(1):57-65, 2010

Elzi L, Erb S, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M; for the Swiss HIV Cohort Study. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. Arch Intern Med. 172:1313-1321, 2012, Accomp.

Marzolini C, Mueller R, Li-Blatter X, Battegay M, Seelig A. The Brain Entry of HIV-1 Protease Inhibitors Is Facili-tated When Used in Combination. Mol Pharm. 10(6):2340-9; 2013.

Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, Passweg J, Khanna N. Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Rele-vant Mold Infections. J Infect Dis. pii: jiu607. [Epub ahead of print]; 2014.

Imprint Privacy policy « This page (revision-4) was last updated on Monday, 19. December 2016, 12:29 by Kaiser Dana
  • operated by